Koninklijke Philips (PHIA) Stock Overview
Operates as a health technology company in North America, the Greater China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
PHIA Community Fair Values
Create NarrativeSee what 80 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Koninklijke Philips N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €23.16 |
| 52 Week High | €27.70 |
| 52 Week Low | €21.44 |
| Beta | 0.92 |
| 1 Month Change | -3.06% |
| 3 Month Change | -1.53% |
| 1 Year Change | 4.75% |
| 3 Year Change | 25.93% |
| 5 Year Change | -35.66% |
| Change since IPO | 1,969.09% |
Recent News & Updates
PHIA: Future Hospital Partnerships And AI Imaging Will Support Balanced Outlook
Analysts have raised their price target for Koninklijke Philips from €19.60 to €22.60, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and a modest adjustment to future P/E expectations. What’s in the News for Koninklijke Philips Royal Philips launched the Alturion ultrasound system, which integrates AI-powered workflows, Elevate Plus measurements, and a connected ecosystem, following FDA 510(k) clearance and CE mark certification for use in the USA and Europe.
PHIA: AI Ultrasound And Monitoring Alliance Will Drive Future Upside Potential
Analysts have lifted their fair value estimate for Koninklijke Philips, with the price target moving from about €26.68 to roughly €27.93. They cite updated assumptions around revenue growth, profit margins and a lower future P/E multiple as key drivers of the change.Recent updates
PHIA: Future Hospital Partnerships And AI Imaging Will Support Balanced Outlook
Analysts have raised their price target for Koninklijke Philips from €19.60 to €22.60, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and a modest adjustment to future P/E expectations. What’s in the News for Koninklijke Philips Royal Philips launched the Alturion ultrasound system, which integrates AI-powered workflows, Elevate Plus measurements, and a connected ecosystem, following FDA 510(k) clearance and CE mark certification for use in the USA and Europe.PHIA: AI Ultrasound And Monitoring Alliance Will Drive Future Upside Potential
Analysts have lifted their fair value estimate for Koninklijke Philips, with the price target moving from about €26.68 to roughly €27.93. They cite updated assumptions around revenue growth, profit margins and a lower future P/E multiple as key drivers of the change.Koninklijke Philips (ENXTAM:PHIA) Stock Could Be 32.5% Undervalued After WellSpan Alliance
Koninklijke Philips (ENXTAM:PHIA) is back in focus after a seven-year alliance with WellSpan Health and US clearance for its Elevate Plus AI ultrasound platform, which highlights its push into health technology and digital diagnostics. See our latest analysis for Koninklijke Philips. Alongside the WellSpan alliance and US clearance for Elevate Plus, Koninklijke Philips shares have recently gained some traction, with a 6.27% 1 month share price return but a 3 month decline of 3.65%. The 1 year...Koninklijke Philips N.V. Just Recorded A 123% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a good week for Koninklijke Philips N.V. ( AMS:PHIA ) shareholders, because the company has just released its...Koninklijke Philips N.V. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a good week for Koninklijke Philips N.V. ( AMS:PHIA ) shareholders, because the company has just released its...These 4 Measures Indicate That Koninklijke Philips (AMS:PHIA) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Koninklijke Philips' (AMS:PHIA) Earnings Offer More Than Meets The Eye
Koninklijke Philips N.V.'s ( AMS:PHIA ) recent earnings report didn't offer any surprises, with the shares unchanged...Shareholder Returns
| PHIA | NL Medical Equipment | NL Market | |
|---|---|---|---|
| 7D | -2.1% | -1.6% | 0.3% |
| 1Y | 4.7% | -23.7% | 39.7% |
Return vs Industry: PHIA exceeded the Dutch Medical Equipment industry which returned -23.7% over the past year.
Return vs Market: PHIA underperformed the Dutch Market which returned 39.7% over the past year.
Price Volatility
| PHIA volatility | |
|---|---|
| PHIA Average Weekly Movement | 3.7% |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in NL Market | 7.7% |
| 10% least volatile stocks in NL Market | 2.2% |
Stable Share Price: PHIA has not had significant price volatility in the past 3 months compared to the Dutch market.
Volatility Over Time: PHIA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1891 | 64,317 | Roy W. Jakobs | www.philips.com |
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices.
Koninklijke Philips N.V. Fundamentals Summary
| PHIA fundamental statistics | |
|---|---|
| Market cap | €22.49b |
| Earnings (TTM) | €968.00m |
| Revenue (TTM) | €17.64b |
Is PHIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHIA income statement (TTM) | |
|---|---|
| Revenue | €17.64b |
| Cost of Revenue | €9.67b |
| Gross Profit | €7.97b |
| Other Expenses | €7.01b |
| Earnings | €968.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 28, 2026
| Earnings per share (EPS) | 1.00 |
| Gross Margin | 45.20% |
| Net Profit Margin | 5.49% |
| Debt/Equity Ratio | 70.9% |
How did PHIA perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/26 02:25 |
| End of Day Share Price | 2026/07/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Koninklijke Philips N.V. is covered by 33 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Óscar Rodriguez Rouco | Banco de Sabadell. S.A. |
| null null | Banco de Sabadell. S.A. |
| Carlos Javier Treviño Peinador | Banco Santander |